Nuvectis Pharma Inc (NVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 31,634 | 18,533 | 19,126 | 19,993 | 5,742 |
| Other current assets | 75 | 74 | 59 | 412 | 91 |
| TOTAL | $31,709 | $18,607 | $19,185 | $20,405 | $5,833 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 824 |
| TOTAL | $N/A | $N/A | $N/A | $N/A | $824 |
| Total Assets | $31,709 | $18,607 | $19,185 | $20,405 | $6,657 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 13,181 | 8,054 | 6,569 | 5,741 | 2,024 |
| Accrued Expenses | 115 | 840 | 415 | 445 | 395 |
| TOTAL | $13,296 | $8,894 | $6,984 | $6,186 | $2,419 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 15,246 |
| TOTAL | $N/A | $N/A | $N/A | $N/A | $15,246 |
| Total Liabilities | $13,296 | $8,894 | $6,984 | $6,186 | $17,665 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 26,492 | 23,392 | 17,769 | 14,752 | 12,718 |
| Retained earnings | -99,687 | -73,245 | -54,245 | -31,985 | -12,900 |
| TOTAL | $18,413 | $9,713 | $12,201 | $14,219 | $-11,008 |
| Total Liabilities And Equity | $31,709 | $18,607 | $19,185 | $20,405 | $6,657 |